FDA decision: Ivonescimab by Summit Therapeutics (in 2026)
44.0 pts (24h)ChinaOne-OffHealth & Medicine4m
KalshiComprobar disponibilidadKYC requerido2% de comisiónDatos de resolución verificadosCalibración aceptableProbabilidad implícita actual
Sí 93%+44.0pt
Calidad del mercado
49 / 100
Baja calidadVolumen 24h
673,1 €
Liquidez
1,8 mil €
Baja liquidezCompra / Venta
62.0% / 70.0%
Spread
8.0 pt
Spread amplioDatos de mercado
Actualizado hace 17 minutos
17 jun 26, 21:001 ene 27, 4:59
Tendencias
Reglas
If the FDA's decision on Ivonescimab by Summit Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
Liquida mediante:AppliedXL
- This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
- Ivonescimab (also called AK112 or SMT112) is a bispecific antibody — think of it as a single engineered drug molecule that carries two different "hooks" instead of one, allowing it to grab and block two disease-promoting proteins at the same time.
- It was developed by Akeso and is being commercialized outside China by Summit Therapeutics.
- By simultaneously neutralizing both targets, ivonescimab is designed to slow cancer growth more effectively than drugs that block only one pathway at a time.
- This market and these products have not been endorsed by any aforementioned brands or its affiliates.
Mercados abiertos
China
POLYMARKETCounter-Strike: The Huns Esports vs DEPO (BO3) - IEM Beijing: Asian Qualifier Playoffs
- Match Winner+5.5pt48%
- O/U 2.5 Games-2.5pt45%
- 144%
+1 resultados más
- Volumen total
- 39,1 mil €
- Volumen 24h
- 37,9 mil €
POLYMARKETBest Chinese AI Company end of September?
- Alibaba+16.5pt76.8%
- Moonshot-9.8pt13.1%
- Z.ai-6.5pt6.1%
+8 resultados más
POLYMARKETCounter-Strike: MIBR vs Eternal Fire (BO3) - IEM Beijing: Global Qualifier Playoffs
- Match Winner-1.5pt61%
- 2 Winner-5.5pt57%
- 1 Winner-1.5pt55%
+5 resultados más
POLYMARKETXi Jinping out before 2027?
- No-0.3pt95%
- Yes+0.3pt5%
- Volumen total
- 11,1 M €
- Volumen 24h
- 21,2 mil €
POLYMARKETWill China invade Taiwan by end of 2026?
- No+0.1pt96%
- Yes-0.1pt4%
- Volumen total
- 34,9 M €
- Volumen 24h
- 18,7 mil €
POLYMARKETCounter-Strike: Nuclear TigeRES vs GamerLegion (BO3) - IEM Beijing: Global Qualifier Playoffs
- 1 Total Rounds: Over/Under 21.552%
- 1 Winner+2.0pt50%
- 3 Total Rounds: Over/Under 21.550%
+6 resultados más
- Counter-Strike: DENDELE CS vs EYEBALLERS (BO3) - IEM Beijing: Global Qualifier Playoffs
- Will a Chinese company have a top ___ AI model by December 31?
- Highest temperature in Beijing on September 2?
- Top Chinese AI Company week of September 7th
- Who will be removed from Chinese Military Companies list by June 30, 2027?
- Will Xi Jinping visit US by which date?
- Will China invade Taiwan by September 30, 2026?
- Counter-Strike: Color vs B8 (BO3) - IEM Beijing: Global Qualifier Playoffs
- DEPO vs. The Huns Esports
- Nothing Ever Happens: 2026
Preguntas frecuentes
- ¿Cuáles son las probabilidades actuales de FDA decision: Ivonescimab by Summit Therapeutics (in 2026)?
- Kalshi cotiza Yes al 93% a fecha de 1 de septiembre de 2026.
- ¿Cuándo se resuelve FDA decision: Ivonescimab by Summit Therapeutics (in 2026)?
- Está previsto que FDA decision: Ivonescimab by Summit Therapeutics (in 2026) se resuelva el 1 de enero de 2027.
- ¿Cómo se liquida FDA decision: Ivonescimab by Summit Therapeutics (in 2026)?
- Kalshi liquida este mercado del siguiente modo: If the FDA's decision on Ivonescimab by Summit Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.